Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8765839 | 0.85 | MEN1 (0.38) | HSD11B1EPHX1TSHREPHX2FKBP1A | |
| SCHEMBL8395211 | 0.82 | HSD11B1 (0.47) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL26330100 | 0.79 | TSHR (0.38) | HSD11B1TSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL20768339 | 0.79 | HSD11B1 (0.44) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL3961156 | 0.79 | HSD11B1 (0.44) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL418793 | 0.79 | HSD11B1 (0.44) | HSD11B1EPHX1TSHREPHX2FKBP1A | |
| SCHEMBL12065392 | 0.78 | HSD11B1 (0.34) | HSD11B1EPHX1TSHRCHRM2CHRM4 | |
| SCHEMBL8103089 | 0.78 | CYP2C9 (0.37) | HSD11B1EPHX1CYP2C9CHRM2CHRM4 | |
| SCHEMBL1033337 | 0.78 | HSD11B1 (0.52) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL5350579 | 0.78 | HSD11B1 (0.52) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201516-B2 | Targeting K-Ras-mediated signaling pathways and malignancy by prostratin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-12 | — | — | US | claimed |
| US-20170326093-A1 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY PROSTRATIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-16 | — | — | US | claimed |
| EP-3191092-A1 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY PROSTRATIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040656-A1 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY PROSTRATIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-17 | — | — | WO | claimed |
| US-20050222158-A1 | Method of treating migraine headaches using calcitonin gene related peptide mimetics | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-06 | — | — | US | claimed |
| US-20050209256-A1 | Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists | MYRIAD GENETICS, INC. | 2005-09-22 | — | — | US | claimed |
| EP-4689033-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | The Procter & Gamble Company (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211640-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| US-10201516-B2 | Targeting K-Ras-mediated signaling pathways and malignancy by prostratin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170351179-A1 | COMPOSITION FOR FORMING UPPER LAYER FILM, PATTERN FORMING METHOD USING THE SAME, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170326093-A1 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY PROSTRATIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3191092-A1 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY PROSTRATIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-19 | — | — | EP | disclosed |
| CN-101400637-A | Process for producing adamantyl (mono-or poly-) acetic acid and process for producing adamantyl (mono-or poly-) ethanol using the same | IDEMITSU KOSAN CO (JP) | 2009-04-01 | — | — | CN | disclosed |
| WO-2008078580-A1 | ADAMANTYL ETHANOL AND PROCESS FOR PRODUCTION THEREOF | IDEMITSU KOSAN CO., LTD. (JP) | 2008-07-03 | — | — | WO | disclosed |
| US-7338755-B2 | Photosensitive composition and method for forming pattern using same | KABUSHIKI KAISHA TOSHIBA (JP) | 2008-03-04 | — | — | US | disclosed |
| US-20070224549-A1 | PHOTOSENSITIVE COMPOSITION AND METHOD FOR FORMING PATTERN USING SAME | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20050222158-A1 | Method of treating migraine headaches using calcitonin gene related peptide mimetics | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-06 | — | — | US | disclosed |
| US-20050209256-A1 | Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists | MYRIAD GENETICS, INC. | 2005-09-22 | — | — | US | disclosed |
| CN-87104184-A | PHOTOCHROMIC SPIROPYRAN COMPOUNDS | — | 1988-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222158-A1 | Method of treating migraine headaches using calcitonin gene related peptide mimetics | CALCRL, CALCB, CALCA | HSD11B1 3902/4885EPHX1 2158/4885TSHR 299/4885 |
| US-20170326093-A1 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY PROSTRATIN | KRAS, HRAS, RASGRP1 | HSD11B1 1149/4885EPHX1 1421/4885TSHR 962/4885 |
| US-10201516-B2 | Targeting K-Ras-mediated signaling pathways and malignancy by prostratin | KRAS, HRAS, RASGRP1 | HSD11B1 1149/4885EPHX1 1421/4885TSHR 962/4885 |
| US-20050209256-A1 | Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists | CALCRL, CALCB, CALCA | HSD11B1 3919/4885EPHX1 2349/4885TSHR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.